Terlipressin

Mechanism

A modified vasopressin that preferentially constricts the blood vessels feeding the gut (splanchnic circulation). Approved in 2022 for hepatorenal syndrome — a life-threatening condition where the kidneys shut down due to advanced liver disease. It works by redirecting blood flow from the dilated splanchnic vessels back to the kidneys, restoring kidney function.

Effects

## Detailed Effects — Terlipressin ### Hepatic / Splanchnic Circulation [Tier 1] - Synthetic vasopressin analog — triglycyl-lysine vasopressin. A prodrug that is slowly cleaved to release lysine vasopressin, providing sustained V1 receptor activation. - Preferentially constricts splanchnic arterioles (V1aR) → reduces portal pressure and splanchnic blood flow → redirects blood flow to the kidneys. - This splanchnic vasoconstriction reverses the pathological vasodilation that causes hepatorenal syndrome (HRS) — the kidneys are structurally normal but hypoperfused due to severe portal hypertension-driven vasodilation. - **CONFIRM Trial (Wong et al., NEJM 2021, n=300)**: Terlipressin vs placebo for hepatorenal syndrome type 1 (HRS-1). Verified reversal of HRS: 32% vs 17% (p=0.006). Led to FDA approval in 2022. - Also reduces variceal bleeding by reducing portal venous pressure — used for acute esophageal variceal hemorrhage in many countries (not FDA-approved for this in the US). ### Renal System [Tier 1] - Reverses functional renal failure in HRS by improving renal perfusion pressure. - Increases GFR by redirecting blood flow from dilated splanchnic circulation to renal arteries. - Combined with albumin infusion (standard co-treatment), produces sustained improvement in creatinine. ### Cardiovascular System [Tier 1] - Systemic vasoconstriction via V1aR → increases mean arterial pressure. - Cardiac complications are the major safety concern: ischemic events (cardiac, mesenteric, digital), arrhythmias, and fluid overload. - CONFIRM trial: respiratory failure occurred in 11% vs 2% (mainly pulmonary edema), overall serious adverse events higher with terlipressin. ### GI System [Tier 1-2] - Reduces portal hypertension → reduces variceal bleeding risk. - May cause abdominal cramps, diarrhea (GI smooth muscle contraction via V1 receptors). - Used for acute variceal hemorrhage in Europe, Asia, and Latin America (not FDA-approved for this indication in the US).

Practitioner Guide

## Practitioner Guide — Terlipressin ### FDA-Approved Indication - Hepatorenal syndrome type 1 (HRS-1) with rapid deterioration of renal function in adults. - Brand name: Terlivaz. FDA-approved September 2022. ### Dosing Protocol (HRS-1) - **Starting dose**: 0.85 mg IV bolus every 6 hours (infused over 2 minutes). - **Dose titration**: If serum creatinine has not decreased by ≥30% from baseline by Day 4, increase to 1.7 mg IV every 6 hours. - **Maximum dose**: 1.7 mg IV every 6 hours. - **Duration**: Continue until HRS reversal (serum creatinine ≤1.5 mg/dL on 2 consecutive values ≥2 hours apart) or up to 14 days. Discontinue if no improvement by Day 14. - **Co-treatment**: Albumin 1 g/kg on Day 1 (max 100 g), then 20-40 g/day as needed for volume expansion. ### Patient Selection (CRITICAL) - **Use in**: Hospitalized patients with cirrhosis and HRS-1 (rapidly progressive AKI, doubling of creatinine to >2.5 mg/dL in <2 weeks, no response to albumin/diuretic withdrawal). - **Do NOT use in**: Patients with MELD score >35 (higher mortality risk without clear benefit), patients with ongoing septic shock, respiratory failure at baseline, coronary/mesenteric/peripheral ischemia. - **REMS Program**: Terlivaz has a REMS (Risk Evaluation and Mitigation Strategy) requiring healthcare facilities to educate staff on respiratory failure risk. ### Monitoring (Intensive) - **Respiratory**: SpO2 monitoring. Assess for pulmonary edema at least every 6 hours. Hold or discontinue if SpO2 drops, respiratory distress develops. - **Hemodynamic**: BP, HR monitoring. Hold if severe hypertension or bradycardia. - **Renal**: Daily serum creatinine. Target: return to ≤1.5 mg/dL. - **Ischemia surveillance**: Daily abdominal exam, cardiac enzymes if chest pain, extremity perfusion checks. - **Volume status**: Daily weights, I/Os, lung auscultation. Diuretics may be needed to manage fluid overload. ### Storage - Terlivaz vial: Store at room temperature (20-25°C). Do not freeze. - Reconstitute with supplied diluent. Use within 48 hours if refrigerated after reconstitution.

Evidence

• Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome

  Florence Wong et al. (2021) — N Engl J Med — PMID: 33657294

  In the CONFIRM phase 3 trial (n=300), verified HRS reversal occurred in 32% of terlipressin-treated patients versus 17% with placebo (P=0.006), with higher rates of HRS reversal without renal replacement therapy by day 30. Benefit was offset by more adverse events, including respiratory failure; FDA safety communications also warn about serious or fatal respiratory failure.

  strong

Research Summary

## Research Summary — Terlipressin ### Tier 1: Randomized Controlled Trials - **CONFIRM Trial (Wong et al., NEJM 2021, n=300)**: Pivotal Phase 3 RCT. Terlipressin + albumin vs placebo + albumin for HRS-1. Verified HRS reversal: 32% vs 17% (p=0.006). But: no significant difference in 90-day transplant-free survival (OR 1.08). Higher adverse events including respiratory failure (11% vs 2%). Led to FDA approval with REMS. - **REVERSE Trial (Boyer et al., NEJM 2016, n=196)**: Phase 3 RCT. Terlipressin improved HRS reversal but did not reach statistical significance for primary endpoint. Contributed to understanding of optimal patient selection. - **Multiple European RCTs**: Terlipressin has been standard of care for HRS in Europe for over a decade. Meta-analyses of these trials showed consistent HRS reversal benefit. ### Tier 2: Systematic Reviews & Meta-Analyses - Cochrane Review of vasoconstrictors for HRS: terlipressin + albumin is the most studied and most effective vasoconstrictor regimen for HRS. - AASLD and EASL guidelines recommend terlipressin as first-line vasoconstrictor for HRS-1 (where available). - Meta-analysis by Cavallin et al. (Hepatology 2016): terlipressin improved short-term survival in HRS when combined with albumin. ### Tier 3: Case Reports & Practitioner Protocols - Hepatologists report best outcomes when terlipressin is started early in HRS course, before creatinine rises above 5 mg/dL. - European practitioners have extensive clinical experience (20+ years) and use continuous infusion (2-12 mg/day) as an alternative to bolus dosing — may reduce ischemic complications. - Practitioners universally combine with albumin — terlipressin alone is insufficient. ### Gaps - Continuous infusion vs bolus dosing comparison in a large RCT is needed. - Optimal patient selection to maximize benefit/risk ratio — MELD score cutoffs are debated. - 90-day survival benefit remains unproven despite HRS reversal — suggests HRS reversal is a surrogate, not a definitive endpoint. ### Active Trials - Post-marketing studies as required by REMS. - Studies of continuous infusion protocols to reduce respiratory complications. - Trials combining terlipressin with other emerging HRS therapies.